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In this study fourteen novel cobalt (II) or zinc (II) complexes of benzimidazoles were synthesized from
the 1-(4-substitutedbenzyl)-1H-benzimidazoles and CoCl2$6H2O or ZnCl2. Cytotoxic activities of novel
complexes were investigated against lung cancer cells (A549) and BEAS-2B. Three of the examined
compounds (1, 4 and 5) showed high cytotoxic activity against A549. While the IC50 of the cisplatin was
2.56 mg/mL for A549 cells at 72 h, the IC50 values of compounds 1, 4 and 5 were 1.97, 1.87 and 1.9 mg/mL,
respectively. IC50 values of these compounds for BEAS-2B cells were higher than the IC50 values for A549.
While the IC50 values for BEAS-2B cells were 59.8, 24.5 and 32.67 mg/mL, respectively, the IC50 of the
cisplatin was determined as 2.53 mg/mL in the present work. Three of the compounds have also high
antimicrobial activity against all the microorganisms used.
© 2016 Elsevier B.V. All rights reserved.1. Introduction
Benzimidazole derivatives are interesting heterocycles because
they are present in many naturally occurring products and various
drugs. They also an important pharmacophore in modern drug
discovery and continue to be the most versatile class of compounds
possessing different pharmacological activities such as antitumor
[1e3], antiulcer [4,5], antifungal [6,7], antibacterial [8e10], anti-
helmintic [11], anti-inflammatory [12e14], anticonvulsant [15],
antitubercular [16e18], antidepressant [19], antihypertensive
[20,21], anticoagulant [22] and antiviral [23,24].
Moreover, benzimidazole is of a considerable interest as a ligand
toward transition metal ions with a variety of biological molecules
including ionheme systems, vitamin B12 and its derivatives, and
severalmetalloproteins. For this reason, the complexes of transition
metal salts with benzimidazole derivatives have been extensivelyApohan), hasan.kucukbay@studied as a model structure of some important biological mole-
cules. Metal complexes of biological important ligands are some-
times more active than free ligands [25]. It has been reported that
the transition metal complexes with a ligand containing benz-
imidazole bearing trimethylsilylpropyl exhibit high antitumor ac-
tivity [26]. Among the cancer types, lung cancer is a common cause
of cancer-related death worldwide [27]. It is responsible from 1.3
million deaths annually across the world. In Turkey, the age-
standardized incidence of lung cancer was found to be 75.8/
100,000 population in men and 9.6/100,000 population in women
[28]. Its incidence and mortality is 52.5/100,000 and 48.7/100,000
per year in the world, respectively [29]. Lung cancer is heteroge-
neous and consists of small cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC) [30]. The most common subtype NSCLC
is responsible from nearly 80 to 90% of all lung cancers [29,31e33].
Despite novel molecular therapies, the 5-year relative survival rate
of patients diagnosed with NSCLC is only 17% [29,32,34]. Conven-
tional treatments of NSCLC are fairly ineffective [31]. Chemotherapy
resistance is one of the main reasons leading to the failure of
chemotherapy [35]. Therefore, there is an urgent need for novel
drugs with an improved efficacy against NSCLC.
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cooper (II), iron (II), nickel (II) and zinc (II)) complexes have been
synthesized successfully and their physical and spectroscopic
properties including single crystal x-ray analysis results reported
[36e38]. More recently, antitumor properties of some benzimida-
zolium ligands were determined and promising results obtained
[39].
According to the literature knowledge and our previous studies
[36e40], in this study it was aimed to synthesized new cobalt(II)
and zinc(II) complexes incorporating benzyl-substituted benz-
imidazole complexes (Scheme 1) in attempt to obtain possible
active compounds having cytotoxic activities against cancer cell
lines A549 and BEAS-2B and antimicrobial activities against Gram
positive (S. aureus and E. faceium) and Gram negative bacteria
(E. coli and P. aeruginosa) and a yeast, Candida albicans.
2. Experimental
The starting materials and reagents used in the reactions were
supplied commercially by Acros, Aldrich or Merck Chemical Co. 1H
NMR (300.13 MHz) and 13C NMR (75.47 MHz) spectra were recor-
ded using a Bruker Avance 300 MHz Ultrashield high performance
digital FT NMR spectrometer. Infrared spectra were recorded using
an ATR unit from on a Perkin-Elmer FT-IR spectrophotometer. UV-
Vis spectra were measured on a Perkin-Elmer Lambda 35 spectro-
photometer. Elemental analyses were performed with a LECO
CHNS-932 elemental analyzer. Melting points were recorded using
an electrothermal-9200 melting point apparatus and are
uncorrected.
1-(4-Chlorobenzyl)-1H-benzimidazole (I), 1-(4-bromobenzyl)-
1H-benzimidazole (II), 1-(4-tolylbenzyl)-1H-benzimidazole (III), 1-
(4-cyanobenzyl)-1H-benzimidazole (IV), 1-(4-methoxybenzyl)-1H-
benzimidazole (V), 1-(4-nitrobenzyl)-1H-benzimidazole (VI), 1-(4-
vinylbenzyl)-1H-benzimidazole (VII) were synthesized according
to the literature procedures [41e46]. Compounds (1e14) were
synthesized from 1-(4-substitutedbenzyl)-1H-benzimidazole with
ZnCl2 and CoCl2  6H2O in EtOH (Scheme 1).
2.1. Synthesis
2.1.1. Synthesis of dichlorobis[1-(4-chlorobenzyl)-1H-
benzimidazole-KN
3]zinc (II), (1)
A mixture of 1-(4-chlorobenzyl)-1H-benzimidazole (2.00 g,
8.24mmol), ZnCl2 (0.56 g, 4.12mmol) and EtOH (20mL)was heated
under reflux for 4 h and then the mixture was cooled to roomScheme 1. Synthesis pathways of ttemperature and filtered off. White colored solid was crystallized
with DMF/EtOH (1:2) (10 mL). White crystals of the title compound
were washed with diethyl ether/n-hexane (1:1) and dried under
ambient atmosphere. Yield: 2.25 g, 88%, m.p.: 257e258 C. Anal.
Calcd for C28H22Cl4N4Zn (%): C, 54.09; H, 3.57; N, 9.01. Found (%): C,
53.96; H, 3.63; N, 8.89. IR: n(C]N): 1489 cm1. 1H NMR (DMSO-d6,
300 MHz): d 5,65 (s, 4H, CH2), 7.28e7.43 (m, 12H, Ar-H), 7.61e7.67
(m, 2H, Ar-H), 7.84e7.90 (m, 2H, Ar-H), 8.90 (s, 2H, NCHN). 13C NMR
(DMSO-d6, 75.5 MHz): d 47.9 (CH2), 112.2, 118.9, 123.8, 124.3, 129.3,
130.0, 133.2, 133.3, 135.5, 140.8 (Ar-C), 145.5 (NCHN) ppm.
Similarly, the compounds of 3, 5, 7, 9,11 and 13were obtained by
the reaction of 1-(4-bromobenzyl)-1H-benzimidazole, 1-(4-
tolylbenzyl)-1H-benzimidazole, 1-(4-cyanobenzyl)-1H-benzimid-
azole, 1-(4-methoxybenzyl)-1H-benzimidazole, 1-(4-nitrobenzyl)-
1H-benzimidazole, 1-(4-vinylbenzyl)-1H-benzimidazole with
ZnCl2 and 2, 4, 6, 8, 10, 12 and 14 with CoCl2 x 6H2O, respectively.
2.1.2. Dichlorobis[1-(4-clorobenzyl)-1H-benzimidazole-KN
3]cobalt
(II), (2)
Yield: 2.28 g (blue crystals), 90%, m.p.: 254e255 C. Anal. Calcd
for C28H22Cl4N4Co (%): C, 54.66; H, 3.60; N, 9.11. Found (%): C, 53.90;
H, 3.57; N, 8.83. IR: n(C]N): 1489 cm1.
2.1.3. Dichlorobis[1-(4-bromobenzyl)-1H-benzimidazole-KN
3]zinc
(II), (3)
Yield: 2.26 g (white crystals), 91%, m.p.: 263e264 C. Anal. Calcd
for C28H22Br2Cl2N4Zn (%): C, 47.32; H, 3.12; N, 7.88. Found (%): C,
47.20; H, 3.08; N, 7.92. IR: n(C]N): 1491 cm1. 1H NMR (DMSO-d6,
300 MHz): d 5,61 (s, 4H, CH2), 7.27e7.35 (m, 8H, Ar-H), 7.53e7.64
(m, 6H, Ar-H), 7.82e7.86 (m, 2H, Ar-H), 8.80 (s, 2H, NCHN). 13C NMR
(DMSO-d6, 75.5 MHz): d 47.9 (CH2), 112.0, 119.1, 121.7, 123.5, 124.1,
130.3, 132.2, 133.4, 136.1, 141.3 (Ar-C), 145.3 (NCHN) ppm.
2.1.4. Dichlorobis[1-(4-bromobenzyl)-1H-benzimidazole-KN
3]
cobalt (II), (4)
Yield: 2.14 g (blue crystals), 87%, m.p.: 262e263 C. Anal. Calcd
for C28H22Br2Cl2N4Co (%): C, 47.76; H, 3.15; N, 7.96. Found (%): C,
47.07; H, 3.20; N, 7.73. IR: n(C]N): 1491 cm1.
2.1.5. Dichlorobis[1-(4-tolylbenzyl)-1H-benzimidazole-KN
3]zinc (II),
(5)
Yield: 2.13 g (white crystals), 82%, m.p.: 238e239 C. Anal. Calcd
for C30H28Cl2N4Zn (%): C, 62.03; H, 4.86; N, 9.64. Found (%): C, 61.27;
H, 4.91; N, 9.62. IR: n(C]N): 1483 cm1. 1H NMR (DMSO-d6,
300 MHz): d 2.25 (s, 6H, CH3) 5,57 (s, 4H, CH2), 7.13e7.32 (m, 12H,he benzimidazole complexes.
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NCHN). 13C NMR (DMSO-d6,75.5 MHz): d 21.1 (CH3), 48.5 (CH2),
112.2, 118.9, 123.6, 124.1, 128.1, 129.8, 133.4, 133.5, 137.8, 140.9 (Ar-
C), 145.3 (NCHN) ppm.
2.1.6. Dichlorobis[1-(4-tolylbenzyl)-1H-benzimidazole-KN
3]cobalt
(II), (6)
Yield: 2.20 g (blue crystals), 85%, m.p.: 235e236 C. Anal. Calcd
for C30H28Cl2N4Co (%): C, 62.73; H, 4.91; N, 9.75. Found (%): C, 61.74;
H, 4.84; N, 9.59. IR: n(C]N): 1483 cm1.
2.1.7. Dichlorobis[1-(4-cyanobenzyl)-1H-benzimidazole-KN
3]zinc
(II), (7)
Yield: 2.35 g (white crystals), 91%, m.p.: 213e214 C. Anal. Calcd
for C30H22Cl2N6Zn (%): C, 59.77; H, 3.68; N, 13.94. Found (%): C,
59.62; H, 3.63; N, 13.81. IR: n(C]N): 1482, n(C^N): 2233 cm1. 1H
NMR (DMSO-d6, 300 MHz): d 5,73 (s, 4H, CH2), 7.29e7.85 (m, 16H,
Ar-H), 8.78 (s, 2H, NCHN). 13C NMR (DMSO-d6, 75.5 MHz): d 47.6
(CH2), 110.7 (CN), 111.4, 118.5, 118.7, 123.2, 123.7, 128.3, 132.7, 132.9,
140.7, 141.7 (Ar-C), 145.0 (NCHN) ppm.
2.1.8. Dichlorobis[1-(4-cyanobenzyl)-1H-benzimidazole-KN
3]cobalt
(II), (8)
Yield: 2.40 g (blue crystals), 94%, m.p.: 198e200 C. Anal. Calcd
for C30H22Cl2N6Co (%): C, 60.42; H, 3.72; N, 14.09. Found (%): C,
60.68; H, 3.98; N, 13.53. IR: n(C]N): 1482, n(C^N): 2233 cm1.
2.1.9. Dichlorobis[1-(4-methoxybenzyl)-1H-benzimidazole-KN
3]
zinc (II), (9)
Yield: 2.30 g (white crystals), 90%, m.p.: 210e212 C. Anal. Calcd
for C30H28Cl2N4O2Zn (%): C, 58.79; H, 4.60; N, 9.14. Found (%): C,
57.47; H, 4.28; N, 8.75. IR: n(C]N): 1485 cm1. 1H NMR (DMSO-d6,
300 MHz): d 3.70 (s, 6H, OCH3) 5.54 (s, 4H, CH2), 6.90 (d, 4H,
J ¼ 6.6 Hz, Ar-H), 7.28e7.36 (m, 8H, Ar-H), 7.65e7.68 (m, 2H, Ar-H),
7.82e7.85 (m, 2H, Ar-H), 8.80 (s, 2H, NCHN). 13C NMR (DMSO-d6,
75.5 MHz): d 47.7 (OCH3), 55.0 (CH2), 111.7, 114.1, 118.4, 123.0, 123.5,
127.9, 129.2, 132.8, 140.5, 158.9 (Ar-C), 144.1 (NCHN) ppm.
2.1.10. Dichlorobis[1-(4-methoxybenzyl)-1H-benzimidazole-KN
3]
cobalt (II), (10)
Yield: 2.23 g (blue crystals), 87%, m.p.: 208e209 C. Anal. Calcd
for C30H28Cl2N4O2Co (%): C, 59.42; H, 4.65; N, 9.24. Found (%): C,
58.90; H, 4.55; N, 9.17. IR: n(C]N): 1485 cm1.
2.1.11. Dichlorobis[1-(4-nitrobenzyl)-1H-benzimidazole-KN
3]zinc
(II), (11)
Yield: 2.16 g (yellow crystals), 85%, m.p.: 303e304 C. Anal.
Calcd for C28H22Cl2N6O4Zn (%): C, 52.32; H, 3.45; N, 13.07. Found
(%): C, 52.04; H, 3.31; N, 12.89. IR: n(C]N): 1483 cm1. 1H NMR
(DMSO-d6, 300 MHz): d 5,81 (s, 4H, CH2), 7.29e7.35 (m, 4H, Ar-H),
7.53e7.62 (m, 6H, Ar-H), 7.87e7.90 (m, 2H, Ar-H), 8.17e8.22 (m, 4H,
Ar-H), 8.90 (s, 2H, NCHN). 13C NMR (DMSO-d6, 75.5 MHz): d 47.4
(CH2), 111.5, 118.6, 123.3,123.8,123.9, 128.6, 132.8, 140.5, 143.6,147.1
(Ar-C), 145.1 (NCHN) ppm.
2.1.12. Dichlorobis[1-(4-nitrobenzyl)-1H-benzimidazole-KN
3]cobalt
(II), (12)
Yield:2.05 g (green crystals), 82%, m.p.: 300e301 C. Anal. Calcd
for C28H22Cl2N6O4Co (%): C, 52.85; H, 3.48; N, 13.21. Found (%): C,
52.45; H, 3.26; N, 13.14. IR: n(C]N): 1482 cm1.
2.1.13. Dichlorobis[1-(4-vinylbenzyl)-1H-benzimidazole-KN
3]zinc
(II), (13)
Yield: 2.06 g (white crystals), 80%, m.p.: >350 C. Anal. Calcd for
C32H28Cl2N4Zn (%): C, 63.54; H, 4.67; N, 9.26. Found (%): C, 63.14; H,4.58; N, 9.05. IR: n(C]N): 1484 cm1. 1H NMR (DMSO-d6, 300 MHz):
d 5.25 (dd, 2H, 3Jcis ¼ 10.8, 2Jgem ¼ 0.9 Hz, CH]CH2), 5.61 (s, 4H,
CH2), 5.80 (dd, 2H, 3Jtrans ¼ 17.7, 2Jgem ¼ 0.9 Hz, CH]CH2), 6.69 (dd,
2H, 3Jcis ¼ 10.8, 3Jtrans ¼ 17.7 Hz, CH]CH2), 7.28e7.30 (m, 4H, Ar-H),
7.33 (d, 4H, J¼ 8.4 Hz, Ar-H), 7.44 (d, 4H, J¼ 8.1 Hz, Ar-H), 7.61e7.64
(m, 2H, Ar-H), 7.82e7.85 (m, 2H, Ar-H), 8.82 (s, 2H, NCHN). 13C NMR
(DMSO-d6, 75.5 MHz): d 47.9 (CH2), 111.7 (CH]CH2), 135.9 (CH]
CH2), 114.8, 118.4, 123.2, 123.7, 126.5, 127.9, 132.9, 135.6, 136.8, 140.4
(Ar-C), 144.9 (NCHN) ppm.2.1.14. Dichlorobis[1-(4-vinylbenzyl)-1H-benzimidazole-KN
3]cobalt
(II), (14)
Yield: 1.98 g (blue crystals), 77%, m.p.: >350 C. Anal. Calcd for
C32H28Cl2N4Co (%): C, 64.23; H, 4.72; N, 9.36. Found (%): C, 64.05; H,
4.79; N, 9.29. IR: n(C]N): 1483 cm1.2.2. Cell lines and culture conditions
The human cancer lines, lung adenocarcinoma (A549) and
healthy human lung bronchial epithelium cells (BEAS-2B) were
used for in vitro screening experiments. A549 cells were obtained
from Prof. Dr. Fikrettin Sahin (Yeditepe University, Department of
Genetics and Bioengineering, Istanbul/Turkey). The cells were
maintained in RPMI 1640 growth medium containing 10% fetal
bovine serum and 1% penicillin/streptomycin at 37 C in 5% CO2
[47].2.3. Drug treatment and MTT assay for cytotoxicity of compounds
Stock solutions of the benzimidazole metal complexes were
prepared in dimethylsulfoxide (DMSO) and further dilutions were
made with a fresh culture medium (the concentration of DMSO in
the final culture medium was <0.1%). Cytotoxic effects of com-
pounds against the cells were determined by MTT cell proliferation
assay. Briefly, the A549 and BEAS-2B cells were plated in 96 well
plates (5  103 cells/well) for 24 h before treatment with com-
pounds to allow the attachment of the cells to surface of the plate.
They incubated at 37 C in a humidified incubator with 5% CO2 for
24, 48 and 72 h. Then, the tested compounds were added to obtain
the final concentration in the range of (0e100 mg/mL) and the cells
were incubated for 24, 48 and 72 h. After incubation, the cells were
treated with 20 mL of MTT reagent for 4 h at 37 C. Then, the su-
pernatants were removed from the plates and the MTT crystals
obtained were homogenized by adding 100 mL DMSO into each
well. To homogenize the pellets more efficiently, the plates were
shaken for 5 min by shaker. Afterwards, the plates were read under
570 nm wavelengths by Microplate reader (Versa Max Tunable)
[48]. Twelve wells were used for every concentration was repeated
in twelve wells and IC50 values (mg/mL) were defined as the com-
pound concentrations reducing absorbance to 50% of control
values. Cisplatin was also used as a control agent.2.4. Microorganisms used
The microorganisms used for testing the antibacterial and
antifungal activity were Escherichia coli ATCC 25922, Staphylococcus
aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853, Entero-
coccus faecium NJ-1 and Candida albicans, respectively. These mi-
croorganisms are stock cultures in the Biotechnology Laboratory,
Inonu University. Stock cultures of these bacteria and yeast were
maintained on blood agar and sabouraud dextrose agar at þ4 C,
respectively.
Table 1
IC50 (mg/mL) values of benzimidazole -Co(II) and Zn(II) complexes on A549 cells and
BEAS-2B cells.
Compounds Time (hour)
24 48 72
A549 BEAS2B A549 BEAS2B A549 BEAS2B
1 >100 65,67 27,84 59,77 1,97 59,8
2 >100 71,69 >100 51,65 >100 42,23
3 >100 62,95 >100 67 13,77 61,59
4 >100 40,54 >100 28,57 1,87 24,5
5 50,98 37,81 15,02 33,35 1,9 32,67
6 94,18 83,5 98,52 42,18 >100 1,99
7 74,87 58,85 42,68 53,47 9,36 51,55
8 90,67 39,78 23,94 20,76 13,11 12,00
9 >100 41,22 89,01 38,70 28,55 38,24
10 >100 82,26 >100 62,83 36,74 44,66
11 >100 81,71 82,36 67,91 22,36 60,04
12 >100 >100 76,81 >100 37,82 97,24
13 >100 >100 88,73 >100 77,46 >100
14 >100 91,54 >100 84,31 85,07 57,1
Cisplatin 4,44 3,17 2,72 2,60 2,56 2.53
Results are averages of twelve independent experiments.
The compounds (1,4 and 5) showed high cytotoxic activity than cisplatin
against A549 whereas the same compounds showed less cytotoxic activityple
against BEAS-2B.
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The minimum inhibitory concentration (MIC) method was
performed to test the antibacterial and antifungal activity of the
newly synthesized compounds. Because dimethylsulfoxide (DMSO)
has no inhibitory effect on growth of microorganisms in the con-
centration used, the stock solutions of the compounds were pre-
pared by dissolving them in DMSO. The MICs of these compounds
were investigated in sterile 96-well microplate by serial dilution
with distilled water. The plates were incubated at 37 C for 24 h
under static conditions. The lowest concentration of the com-
pounds at which no visible growth was seen was considered as the
MIC.
2.6. Statistical analysis
Experiments were carried out for twelve wells. The results were
expressed as mean ± SD. Statistical analysis was performed using
GraphPad Prism 5. The difference between two groups was
analyzed by 2 way Anova and one way Anova and Nonparametric
Tukey test. A difference with or P < 0.001 (*) or P < 0.05 (**) was
considered statistically significant.
3. Results and discussion
3.1. Synthesis and characterization of the benzimidazole
compounds
The cobalt (II) and zinc (II) complexes were synthesized from the
reaction of the appropriate benzimidazole ligand and metal salt.
The complexes were smoothly crystallized in a DMF/EtOH mixture.
The structures of Zn(II) benzimidazole complexes (1, 3, 5, 7, 9, 11
and 13) were elucidated by 1H NMR, 13C NMR and IR spectrometric
analyses. All spectral data were in agreement with the proposed
structures. Due to paramagnetic properties of Co(II)-benzimidazole
complexes (2, 4, 6, 8, 10, 12 and 14) we could not observed appro-
priate NMR signals even more scans in diluted solvents. For this
reason, the structures of Co(II) benzimidazole complexes were
elucidated by IR and UV-Vis spectrometric and elemental analyses.
IR spectra of the compounds show that the strong n(C]N) bands in
free benzimidazoles at 1489-1495 cm1 shift to 1482-1491 cm1 for
Co(II) and Zn(II) complexes. The bathochromic shift indicates the
coordination of tertiary nitrogen of the ligands to Co (II) and Zn(II)
atoms. These type of bathochromic shifts are also reported in the
literature [25,36e38,49,50]. IR spectra of compound IV showed the
n(C^N) band at 2227 cm1, and this band shifted to 2233 cm1 for
corresponding Co(II) and Zn(II) complexes. IR spectra of compound
VI, showed absorption band at 851,1338 and 1509 cm1 assigned to
nitro group attached to 4-position of the benzyl group. The bands
were observed at 858, 1344 and 1515 cm1 for the corresponding
Co (II) complex (12) and 858, 1344 and 1518 cm1 for the corre-
sponding Zn(II) complex (11). The nitro group frequencies shifted
slightly higher frequency after coordinating the metal atom.
The characteristic CH resonances for the proton at position 2 of
the benzimidazole ligand of Zn(II) complexes (1, 3, 5, 7, 9,11 and 13)
were observed between 8.78 and 8.90 ppm.
As expected, the coordination to the Zn(II) ion shifts the 1H NMR
signals of the complex downfield from those of the free ligands
(Ddz 0.77- to 0.96 ppm) for the proton at position 2 of the benz-
imidazole ring. The protons of methylene in Zn(II) complexes were
not shifted significantly to downfield (Ddz 0.10e0.39 ppm).
The carbon resonances for the carbon at position 2 of the
benzimidazole ligands of Zn(II) complexes (1, 3, 5, 7, 9, 11 and 13)
were observed between 141.1 and 145.5 ppm. The coordination to
the Zn(II) ion shifts the 13C NMR signals of the complex downfieldfrom those of the free ligands (Ddz 0.9- to 2.1 ppm) for the carbon
at position 2 of benzimidazole ring. All other aliphatic and aromatic
protons and carbons were observed at expected regions.
The UV-Vis spectra of free benzimidazoles (IeVII) and its com-
plexes (1e14) were determined in 190e800 nm region in DMSO.
Free substituted benzimidazoles have absorption maxima at
273,5 nm attributed n-p* transitions. In the complexes, these peaks
are shifted to 276.5 nm for the Zn complexes and observed same
value (273.5 nm) for the Co complexes. The DMSO-d6 bands for all
cobalt (II) complexes (2, 4, 6, 8, 10, 12 and 14) were observed as
666.5 nm (є ¼ 219.3 M1 cm1). All the cobalt (II) complexes
showed a single DMSO-d6 band. Since zinc (II) has no unpaired d-
electrons, no absorption peak was observed in the visible region for
these complexes.3.2. Biological activity
3.2.1. Cytotoxicity studies
In order to investigate the cytotoxic effects of newly synthesized
cobalt (II) and zinc (II) benzimidazole complexes on A549 and
BEAS-2B cells, respective cells were incubated with increasing
concentrations (0e100 mg/mL) of compounds for 24, 48 and 72 h,
and then subjected to a MTT assay. Table 1 shows the IC50 (con-
centration required to inhibit tumor cell proliferation by 50%) of the
compounds. Among the 14 compounds tested, compounds 1, 4 and
5 had the highest cytotoxic activity while the IC50 values of com-
pounds 1, 4 and 5 were 1.97, 1.87 and 1.9 mg/mL, respectively. This
value was 2.56 mg/mL for cisplatin. The compounds 3, 7, 8, 9, 10, 11,
12, 13 and 14 showed lower cytotoxic activity with IC50 values
between 9 and 85 mg/mL. The remaining two compounds 2 and 6
showed the least cytotoxic activity with IC50 higher than 100 mg/mL
(Table 1 and Fig. 1 A, B, C, D). According to the results of 72 h in-
cubation it could be stated that the compound 4 containing 4-
bromobenzyl substituent at the position 1 of benzimidazole
ligand was more cytotoxic than the compound 1 containing 4-
chlorobenzyl and compound 5 containing 4-methylbenzyl sub-
stituents on A549 cells. Among the tested 14 complexes, incorpo-
rating zinc(II) metal (1, 3, 5, 7, 9, 11 and 13) showed more
cytotoxicity on A549 cells than the other compounds tested except
compound 4. Compound 4 containing cobalt (II) had also high
Fig. 1. A, B, C and D. Cytotoxicity activity of compound 1, 4, 5 and cisplatin on A549, respectively. E, F, G and H. Cytotoxicity activity of compound 1, 4, 5 and cisplatin on BEAS-2B,
respectively. Data points represent means for experiment±SD of twelve independent wells. 72. h significantly different from respective 24 and 48 h: *p < 0.001.
E. Apohan et al. / Journal of Organometallic Chemistry 828 (2017) 52e5856cytotoxic activity on A549 cells. Yurttas et al. evaluated the anti-
cancer activity of some new1-(2-aryl-2-oxoethyl)-2-[(morpholine-
4-yl)thioxomethyl]benzimidazole derivatives on C6, MCF7 andA549 cell lines and reported the IC50 values for 1-(4-chloropheny)-
2-(2-(morpholine-4-carbonothioyl)-1H-benzo[d]imidazol-1-yl)
ethanone and cisplatin, against A549 cells at 24 h, as 15.66 mg/mL
Fig. 3. Cytotoxic effect of cisplatin and compounds 1, 4 and 5 against BEAS-2B. Com-
pound 1, 4 and 5 significantly different from respective cisplatin **p < 0.05.
Table 2
In vitro antimicrobial activities MIC data (mg/mL) of benzimidazole -Co(II) and Zn(II)
complexes.
Compounds E. coli S. aureus P. aeruginosa E. faecium C. albicans
1 25 6,25 200 12,5 6,25
2 200 6,25 400 100 100
3 100 6,25 400 100 50
4 50 6,25 200 50 12,5
5 50 6,25 200 25 12,5
6 100 6,25 400 200 100
7 100 6,25 400 200 100
8 100 6,25 200 200 100
9 200 6,25 400 400 200
10 100 6,25 400 400 200
11 200 6,25 400 200 200
12 100 6,25 400 100 400
13 50 6,25 400 100 400
14 50 6,25 400 200 400
Ciprofloksasin <0,039 <0,039 <0,039 <0,039
Gentamisin <0,024 <0,024 <0,024 <0,024
Fluconazole <0,024
E. Apohan et al. / Journal of Organometallic Chemistry 828 (2017) 52e58 57and 19 mg/mL, respectively [51]. In our study, IC50 of the cisplatin
was detected as 4.44 mg/mL. Liu et al. suggested that Zn(II) com-
plexes containing bis-benzimidazole derivatives could be candidate
for further evaluation as chemotherapeutic agent for human can-
cers [52]. It was found that one of the newbenzimidazole derivative
was the most cytotoxic against A549 cells at hypoxic conditions
[53].
The cytotoxicity of compounds against human lung bronchial
epithelium cells was also examined. IC50 values of compounds 1, 4
and 5 on BEAS-2B were determined as 59.8, 24.5 and 32.67 mg/mL,
respectively. This value was 2.53 mg/mL for cisplatin (Table 1 and
Fig. 1E, F, G, H). In order to confirm the results, A549 and BEAS-2B
cells lines were treated with compounds 1, 4 and 5 and cisplatin for
72 h at concentration 3 mg/mL. These compounds showed toxic
effect against A549 cells as much as cisplatin, but they were less
toxic than cisplatin on BEAS-2B (Figs. 2 and 3). Liu et al. evaluated
the anticancer activities of two Zinc(II) complexes containing bis-
benzimidazole derivatives and cisplatin against five cancer and
one normal cell lines. They reported that complex 2 demonstrated
higher growth inhibition on MCF-7 human breast carcinoma cells
than cisplatin. The complexes possessed high selectivity between
human cancer and normal cells (HK-2), in comparison with
cisplatin [52].
3.2.2. Antimicrobial studies
The antibacterial and antifungal activities of these newly syn-
thesized compounds were tested by MIC method. Antimicrobial
activity results of the complexes were given in Table 2 with stan-
dard reference compounds ciprofloxacin and gentamicin. Gram-
positive and Gram-negative bacteria have different cell wall
structure. While Gram-positive bacteria have a cell wall containing
thick peptidoglycan the Gram-negative bacteria have a thin layer of
peptidoglycan and also the additional outer membrane. Therefore,
this outer membrane is an additional protective barrier against
chemicals such as antimicrobials [54,55]. The compounds tested in
this work showed antibacterial activity against all the bacteria and
the yeast used. All of the compounds showed high antibacterial
activity against Gram-positive bacterium S. aureus (6.25 mg/mL) but
poor antibacterial activity against Gram-negative P. aeruginosa
(200e400 mg/mL). While the compounds of 1, 4, 5, 13 and 14
showed high antibacterial activity (25e50 mg/mL) against Gram-
negative E. coli, the others showed moderate activity
(100e200 mg/mL) against this bacterium. Among the compounds
used 1, 4 and 5 showed high antibacterial activity against Gram-
positive E. faecium. These three compounds were also effective
antifungal compounds against C. albicans. The position and type of
the substituent on the benzimidazole ring give different biologicalFig. 2. Cytotoxic effect of cisplatin and compounds 1, 4 ve 5 against A549. Compound 4
and 5 significantly different from respective cisplatin **p < 0.05.activity to the compounds [56]. Some compounds are more effec-
tive than the others. The compounds, especially 1, 4 and 5 which
have high antimicrobial activity against all the microorganisms,
also showed low cytotoxicity against healthy human lung bronchial
epithelium cells (BEAS-2B). Because of their low cytotoxic effects
against healthy cells these compounds may be a potential as an
antimicrobial agent.4. Conclusions
The synthesis and cytotoxic activity of fourteen benzimidazole
derivatives have been reported in this work. The cytotoxic activities
of the new benzimidazole metal complexes on human cancer cells
(A549) and normal cells (BEAS-2B) have been evaluated. It can be
concluded from our result that compounds 1, 4 and 5 are more
cytotoxic on A549 cells than cisplatin. On the other hand cisplatin
has higher cytotoxicity on BEAS-2B cells than the compounds.
These compounds are also effective antimicrobial agents. In
conclusion, result of this work has encouraged us to investigate
their anticancer profiles in further studies.Declaration of interest
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